Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Genetics

Clinical Trials

Research

Science

Biotechnology

Agendia

More Like This

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium

Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer

Business Wire associated0

Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025

(Graphic: Business Wire)

Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

(Graphic: Business Wire)

MammaPrint® Reimbursement Indication Extended in Belgium

Personalized biology-based insights (Graphic: Business Wire)

Agendia, Inc. Provides Review of Successful 2024